Log In Get Started

News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No articles were published in the past hour and no major developments were reported.
  • No market-moving economic releases or data prints occurred.
  • No central bank statements, rate decisions, or policy guidance were issued.
  • No major geopolitical incidents or sudden conflict escalations emerged.
  • No significant corporate earnings, deal announcements, or M&A headlines appeared.
  • No regulatory or legislative actions affecting markets were reported.

Latest Articles

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Sep 14, 2026
Nina Shah
Press Releases

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Tenaya Therapeutics announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its gene therapy candidate TN-401 for treating PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The designation is supported by positive interim results from the RIDGE-1 Phase 1b/2 clinical trial, which sho…

TNYA
SkyAI Comments on Forward Industries’ Letter and Reaffirms Strategy
Sep 14, 2026
Avery Klein
Press Releases

SkyAI Comments on Forward Industries’ Letter and Reaffirms Strategy

SkyAI, Inc. announced that its Special Committee has reviewed and rejected Forward Industries' unsolicited all-stock acquisition proposal, deeming it not in shareholders' best interests. The company reaffirmed its commitment to its Solana digital asset treasury strategy, continuing to hold over two million SOL tokens, generating staking revenue, an…

SKYA
Mobilicom Secures Follow-On Production Order from Asia-Based Tier-1 Robotics Customer for the Ground Control Station Solution
Sep 14, 2026
Nina Shah
Press Releases

Mobilicom Secures Follow-On Production Order from Asia-Based Tier-1 Robotics Customer for the Ground Control Station Solution

Mobilicom Limited, a Nasdaq-listed provider of cybersecurity and communication solutions for drones and robotics, announced it has received a follow-on production order from a major Asia-based Tier-1 robotics manufacturer. This order focuses on Mobile Ground Control Stations, supporting ongoing deployment across the customer's military and industri…

MOB
Blink Charging President and CEO, Mike Battaglia, to Present at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026
Sep 14, 2026
Marcus Reed
Press Releases

Blink Charging President and CEO, Mike Battaglia, to Present at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026

Blink Charging Co., a leading electric vehicle (EV) charging equipment provider, announced that its President and CEO Mike Battaglia will present at the H.C. Wainwright 28th Annual Global Investment Conference, discussing recent developments, market trends, and the company’s EnergyConnect announcement. The event is scheduled for September 14, 2026,…

BLNK
Coherent Shares Slide in Pre-Market as AI-Photonics Selling Persists
Sep 14, 2026
Jordan Park
Stock Markets

Coherent Shares Slide in Pre-Market as AI-Photonics Selling Persists

Coherent stock fell about 6.5% in pre-market trading to $285.59 amid continued selling in the AI photonics sector. The drop extends a correction from the stock's 52-week high of $440 and follows a post-earnings rotation that began in mid-August. Strong fiscal Q4 2026 results have not halted the pullback, while multiple insider transactions flagged …

European truckmakers ask EU for three-year postponement of 2030 CO2 rules
Sep 14, 2026
Avery Klein
Stock Markets

European truckmakers ask EU for three-year postponement of 2030 CO2 rules

CEOs of Europe's leading truck and bus manufacturers are urging the European Union to push back the compliance date for the 2030 heavy-duty vehicle CO2 reduction target by three years, citing a lack of charging infrastructure and elevated energy costs that limit adoption of zero-emission vehicles. They also called on policymakers to accelerate infr…

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
Sep 14, 2026
Sofia Navarro
Press Releases

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

Teva Pharmaceutical Industries Ltd. announced that its ordinary shares are now trading directly on the New York Stock Exchange under the ticker symbol TEVA, completing its transition from American Depositary Shares (ADS) to ordinary shares. This milestone aligns with Teva's Pivot to Growth strategy aimed at expanding its innovative medicines portfo…

TEVA
etoro Reports Selected August Business Metrics
Sep 14, 2026
Derek Hwang
Press Releases

etoro Reports Selected August Business Metrics

eToro Group Ltd. released selected business metrics for August 2026 showing a 3% year-over-year increase in assets under administration to $20.2 billion and an 18% rise in funded accounts to 4.36 million. Total capital markets trades increased by 31%, though invested amount per trade declined by 29%. Crypto trades decreased by 4% with a significant…

ETOR
Oxford Lane Capital Corp. Provides August 2026 Net Asset Value Update
Sep 14, 2026
Jordan Park
Press Releases

Oxford Lane Capital Corp. Provides August 2026 Net Asset Value Update

Oxford Lane Capital Corp. announced an unaudited estimate of its net asset value (NAV) per share for August 31, 2026, between $10.34 and $10.64. The company cautioned this estimate is preliminary, not approved by the board, and may materially differ from the September quarter-end NAV. The firm is a closed-end management investment company focused o…

OXLC
FactSet to Host Investor Day on November 10, 2026
Sep 14, 2026
Avery Klein
Press Releases

FactSet to Host Investor Day on November 10, 2026

FactSet Research Systems Inc. has scheduled its Investor Day on November 10, 2026, in New York City and via webcast. The event will feature presentations from the CEO, CFO, and executive leadership about the company’s strategy, product roadmap, and financial outlook, including demonstrations of AI-driven solutions. Presentation materials will be av…

FDS
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
Sep 14, 2026
Maya Rios
Press Releases

Evaxion applies its AI-Immunology™ platform in autoimmune diseases

Evaxion A/S has initiated experimental application of its AI-Immunology™ platform in autoimmune diseases by testing two novel treatment concepts – a tolerogenic vaccine and an autoantibody binder. These approaches aim to target underlying disease pathologies with high specificity, potentially leading to more effective and safer therapies than curre…

EVAX
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Sep 14, 2026
Sofia Navarro
Press Releases

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Akebia Therapeutics has dosed the first patient in its open-label Phase 2 basket trial of ebribafusp, an investigational anti-C3d factor H fusion protein designed to inhibit complement activation in kidney tissue without suppressing the blood complement system. The trial targets rare kidney diseases including IgA nephropathy, lupus nephritis, and C…

AKBA
Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting
Sep 14, 2026
Caleb Monroe
Press Releases

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

Radiopharm Theranostics revealed encouraging interim results from its Phase 2b trial of RAD101, a PET imaging agent targeting fatty acid synthase in suspected recurrent brain metastases. The 93% concordance with MRI and preliminary 86% sensitivity highlight RAD101's potential to improve diagnostic accuracy where current imaging methods are limited.…

RADX
Linkage Global Signs Non-Binding Letter of Intent for Strategic PIPE Investment of Up to $20 Million from Capital Finance Limited
Sep 14, 2026
Marcus Reed
Press Releases

Linkage Global Signs Non-Binding Letter of Intent for Strategic PIPE Investment of Up to $20 Million from Capital Finance Limited

Linkage Global Inc., a US-listed company focused on AI-driven wellness solutions, has signed a non-binding letter of intent with Capital Finance Limited for up to $20 million in a two-tranche PIPE investment. The investment aims to accelerate development of AI-enabled wellness infrastructure and fund a strategic acquisition of an AI hardware manufa…

UZX
Live Oak Bank Named Official Business Bank of UNCW Athletics
Sep 14, 2026
Jordan Park
Press Releases

Live Oak Bank Named Official Business Bank of UNCW Athletics

Live Oak Bank, a subsidiary of Live Oak Bancshares, Inc. (NYSE: LOB), has been named the Official Business Bank of UNCW Athletics under a multi-year agreement. This partnership enhances Live Oak's community presence, particularly in Wilmington, NC, and strengthens its connection with local small businesses and university alumni. The bank continues …

LOB
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
Sep 14, 2026
Sofia Navarro
Press Releases

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis

Nasus Pharma received FDA clearance to start clinical studies for NS002, an investigational intranasal epinephrine powder intended as a needle-free alternative to EpiPen for treating anaphylaxis. The pivotal study is planned for Q4 2026, with topline data expected in Q1 2027, aiming to address a $2 billion market by offering faster and more patient…

NSRX
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
Sep 14, 2026
Priya Menon
Press Releases

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

Telomir Pharmaceuticals announced new research from The Ohio State University demonstrating that their compound Telomir-Zn inhibits cell growth effectively in human and canine osteosarcoma cell lines, suggesting potential for both veterinary and human therapeutic development. The company is advancing its triple-negative breast cancer (TNBC) program…

TELO